Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multimarker scores of Th1 and Th2 immune cellular profiles in peripheral blood predict response and immune related toxicity with CTLA4 blockade and IFNα in melanoma.
Khunger A, Sarikonda G, Tsau J, Pahuja A, Alfonso Z, Gao J, Laing C, Vaupel C, Dakappagari N, Tarhini AA. Khunger A, et al. Among authors: tarhini aa. Transl Oncol. 2021 Mar;14(3):101014. doi: 10.1016/j.tranon.2021.101014. Epub 2021 Jan 12. Transl Oncol. 2021. PMID: 33450703 Free PMC article.
Neoadjuvant therapy of locally/regionally advanced melanoma.
Khunger A, Buchwald ZS, Lowe M, Khan MK, Delman KA, Tarhini AA. Khunger A, et al. Among authors: tarhini aa. Ther Adv Med Oncol. 2019 Jul 31;11:1758835919866959. doi: 10.1177/1758835919866959. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31391869 Free PMC article. Review.
CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma.
Khunger A, Piazza E, Warren S, Smith TH, Ren X, White A, Elliott N, Cesano A, Beechem JM, Kirkwood JM, Tarhini AA. Khunger A, et al. Among authors: tarhini aa. PLoS One. 2021 Jan 11;16(1):e0245287. doi: 10.1371/journal.pone.0245287. eCollection 2021. PLoS One. 2021. PMID: 33428680 Free PMC article. Clinical Trial.
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma.
Najjar YG, McCurry D, Lin H, Lin Y, Zang Y, Davar D, Karunamurthy A, Drabick JJ, Neves RI, Butterfield LH, Ernstoff MS, Puzanov I, Skitzki JJ, Bordeaux J, Summit IB, Bender JO, Kim JY, Chen B, Sarikonda G, Pahuja A, Tsau J, Alfonso Z, Laing C, Pingpank JF, Holtzman MP, Sander C, Rose A, Zarour HM, Kirkwood JM, Tarhini AA. Najjar YG, et al. Among authors: tarhini aa. Clin Cancer Res. 2021 Aug 1;27(15):4195-4204. doi: 10.1158/1078-0432.CCR-20-4301. Epub 2021 Mar 22. Clin Cancer Res. 2021. PMID: 33753453 Free PMC article.
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males.
Saad M, Lee SJ, Tan AC, El Naqa IM, Hodi FS, Butterfield LH, LaFramboise WA, Storkus W, Karunamurthy AD, Conejo-Garcia J, Hwu P, Streicher H, Sondak VK, Kirkwood JM, Tarhini AA. Saad M, et al. Among authors: tarhini aa. J Transl Med. 2022 Jun 3;20(1):253. doi: 10.1186/s12967-022-03450-3. J Transl Med. 2022. PMID: 35659704 Free PMC article.
Neoadjuvant Therapy in Melanoma: Where Are We Now?
Saad M, Tarhini AA. Saad M, et al. Among authors: tarhini aa. Curr Oncol Rep. 2023 Apr;25(4):325-339. doi: 10.1007/s11912-023-01369-6. Epub 2023 Feb 13. Curr Oncol Rep. 2023. PMID: 36781621 Review.
Immune checkpoint blockade and interferon-α in melanoma.
Rafique I, Kirkwood JM, Tarhini AA. Rafique I, et al. Among authors: tarhini aa. Semin Oncol. 2015 Jun;42(3):436-47. doi: 10.1053/j.seminoncol.2015.02.012. Epub 2015 Feb 14. Semin Oncol. 2015. PMID: 25965362 Free PMC article. Review.
197 results